Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Earthworm extract could tame diabetes inflammation

NCT ID NCT07684625

Disease control Sponsor: Universitas Sebelas Maret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether an extract from the earthworm Lumbricus rubellus (DLBS1033) can reduce inflammation and improve quality of life in people with type 2 diabetes. Sixty adults on standard diabetes therapy will receive either a low or high dose of the extract or continue standard care alone for four weeks. Researchers will measure changes in blood markers of inflammation (hs-CRP) and blood vessel health (VEGF), along with self-reported well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lumbricus rubellus (earthworm) extract DLBS1033
What this could lead to
If it works, this could point toward a natural supplement to help control inflammation and blood vessel health in type 2 diabetes.
What could go wrong
This is a small, short-term trial (60 people, 4 weeks). The extract may not reduce inflammation or improve quality of life more than standard diabetes care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

60 people

The number who actually took part.

Started

Mar 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with Type 2 Diabetes Mellitus currently on therapy. * Patients receiving Lumbricus Rubellus extract therapy during outpatient care at the Endocrinology Clinic. * Adults aged \>18 years, both male and female. * Willing to undergo monthly evaluations during the 1-month study period Exclusion Criteria: * Patients with diabetic foot ulcer grade 1-2. * Patients with Diabetic Kidney Disease (DKD) Stage 5. * Patients with chronic liver disease. * Post-operative patients. * Patients with malignancy. * Patients with autoimmune disease or active infection. * Non-compliant or uncooperative patients during the monitoring period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • Dr. Moewardi Regional General Hospital

    Surakarta, Central Java, 57126, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.